A clinical trial published in January of this year, supported the results of previous studies, showing stem cell therapy to be a safe and effective treatment for patients with multiple sclerosis. Traditional, disease modifying treatment is able to reduce flare-ups and slow the progression of MS, however, this type of treatment in unable to repair the damage that has already occurred. The Stem Cells Transplant Institute recommends the use of stem cells derived from umbilical cord tissue for the treatment of multiple sclerosis.
Summary of Study #1: ClinicalTrials.gov Identifier: NCT00273364
The first randomized clinical trial, published in JAMA, January 2019 showed stem cell therapy to be significantly better than current disease-modifying therapy for patients with active relapsing-remitting MS.
Researchers, at the Feinberg School of Medicine at Northwestern Memorial Hospital in Chicago, enrolled 110 patients between September 2005 and July 2016. To qualify, Pptients had to have relapsing-remitting MS, at least 2 relapses while receiving disease-modifying treatment the prior year, and an Expanded Disability Status Scale (EDSS) of 2.0 to 6.0. Researchers at the Feinberg School of Medicine worked with a total of 4 trial sites in the U.S., Europe and South America.
The goal of the study was to compare the nonmyeloablative hematopoietic stem cell therapy to disease modifying therapy on disease progression based on an EDSS score increase of 1.0 or more over a period of 1 year.
One-hundred and ten patients were randomized with 55 patients assigned to receive HSCT along with cyclophosphamide and antithymocyte globulin and 55 patients assigned to receive a higher efficacy or different formulation of DMT than they had received previously. Ninety-eight of the one-hundred and ten patients were evaluated at 1 year and twenty-three of the patients continued to be evaluated every year for a total of five years.
Three patients in the HSCT group experienced disease progression while 34 of the patients in the DMT group experience disease progression. During the first year, EDSS scored improved in the HSCT group while patients in the DMT group experienced a decrease in their EDSS scores. There were no deaths or non-hematopoietic grade 4 toxicities, such as heart attack or sepsis, in the HSCT group.
Summary of Study #2:
ClinicalTrials.gov Identifier: NCT02034188
A one-year Phase 1/2 clinical trial showed stem cell therapy with umbilical cord stem cells is both a safe and effective for patients with multiple sclerosis.
The study “Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis” was published in March of 2018 in the Journal of Translational Medicine.
Twenty patients were enrolled in the one-year phase 1/2 clinical study, designed to evaluate the safety and efficacy of umbilical cord mesenchymal stem cells (MSCs) for the treatment of MS. Four of the 20 patients had primary-progressive MS, 1 patient had secondary-progressive MS and 15 of the patients had relapsing-remitting MS.
Patients received an intravenous infusion of 20 million umbilical cord stem cells each day for 7 days. Positive results were seen one-month post treatment and continued at one-year post treatment.
Patients experienced improvements in; disability, walking time, autonomic function including improvements in bowel and bladder control, sexual function, and overall quality of life. At one year 15 out of 18 patients showed inactive lesions on MRI scans.
No serious adverse events were reported.
Stem Cell Therapy at the Stem Cells Transplant Institute
At the Stem Cells Transplant Institute in Costa Rica, we use umbilical cord stem cells for the treatment of multiple sclerosis.
Stem cell therapy with umbilical cord stem cells could help improve the following symptoms of MS:
- Visual disturbances
- Loss of balance
- Poor coordination
- Slurred speech
- Extreme fatigue
- Problems with memory and concentration
- Bladder and bowel problems
- Sexual dysfunction
- Muscle spasticity
- Sensitivity to heat
- Emotional disturbances
What are the advantages of human umbilical cord mesenchymal stem cells?
- Abundant supply containing up to 10 times more stem cells than bone marrow or adipose derived stem cells
- hUC-MSC have immunosuppressors and immunomodulatory properties that allow their use in any individual without rejection- Human Leukocyte Antigen (HLA) matching is not necessary
- Greater proliferation ability than adult autologous stem cells
- They regenerate at a very rapid rate
- They are young and very adaptive
- They have not been impacted by the aging process
- They have not been affected by environmental toxins
- Umbilical cord stem cells can be administered multiple times over the course of days
- Eliminates the need to collect stem cells from the patient’s fat or hip bone reducing pain and recovery time
Costa Rica has one of the best healthcare systems in world and is ranked among the highest for medical tourism and at the Stem Cells Transplant Institute, we are committed to providing personalized service and the highest quality of care to every patient.
- Richard K. Burt et al., Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple SclerosisA Randomized Clinical Trial JAMA. 2019;321(2):165-174. doi:10.1001/jama.2018.18743
- Neil H. Riordan et al., Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. Journal of Translational Medicine201816:57